The biotech company set the deal at 18.3 million shares priced at $20.50 each and granted underwriters a 30-day option to buy up to 2.745 million additional shares.
Dyne Therapeutics has priced an upsized underwritten public offering of 18,300,000 shares of common stock at $20.50 per share, raising expected gross proceeds of about $375.15 million before discounts, commissions and expenses. All shares are being sold by Dyne, and the offering is expected to close on or about July 23, 2026, subject to customary closing conditions. The company also granted underwriters a 30-day option to purchase up to an additional 2,745,000 shares at the public offering price, less underwriting discounts and commissions. Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers, with LifeSci Capital and Raymond James also serving as joint book-running managers and Jones as lead manager. The sale is being conducted under a shelf registration statement on Form S-3 that became automatically effective upon filing with the SEC on March 5, 2024.